South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million in net sales in the US for the fourth quarter of 2022.
The drug has achieved a meaningful result during the last quarter in the US neutropenia drug market, where Amgen Inc.is a strong player with Neulasta (pegfilgrastim) and Neupogen (filgrastim), said a Hanmi official.
The Korean biotech will accelerate developing other new drug candidates by using Lapscovery, its in-house technology that prolongs the residence time of a biologic and minimizes the frequency of treatment, the official said.
BEAMSTART brings you the latest news, database, and jobs from all around the world on startups, technology, and business. Stay updated with industry news, plug-in to exciting community events, and discover incredible career opportunities with the world's most innovative companies.